Jun. 14 at 10:50 AM
$CTXR $XBI
They’re only doing small offerings right now because they’re waiting on CTOR. CTOR have secured a launch partner and when sales start rolling in, the stock price should rise even more. Eventually, CTXR will reduce its stake in CTOR to free up funds for Mino-Lok, which will keep future offerings at this level very limited.
I’m not sure if Mazur is a genius or a high risk gambler, but we’ll see. If he succeeds, today’s share price could deliver a massive return. We’ve previously talked about 200–300% upside.
Assuming dilution is kept minimal, FDA approval goes smoothly, and they reach
$800 million in sales — with peak sales estimated around
$1.8 billion — just
$800 million in sales could mean an 8,000% return. Biotech stocks typically trade at multiples that could increase this even more.
Buying now will have people calling you either crazy or a genius, depending on execution.
For me, putting a small portion of my portfolio in at this level is worth it. Potential upside++++
